Source comparison
Survodutide vs Semaglutide: Head-to-Head Clinical Outcomes
The SYNCHRONIZE-COMPARE trial, a 48-week randomised controlled study published in The Lancet in late 2025, directly compared survodutide 6.0mg weekly to semaglutide 2.4mg weekly in 1,248 participants with BMI ≥30 or ≥27 with comorbidities. Survodutide produced
This comparison does not assign a generated winner or score.
- The SYNCHRONIZE-COMPARE trial, a 48-week randomised controlled study published in The Lancet in late 2025, directly compared survodutide 6.0mg weekly to semaglutide 2.4mg weekly in 1,248 participants with BMI ≥30 or ≥27 with comorbidities. Survodutide produced 21.2% mean body weight reduction versus 17.4% for semaglutide. A 3.8 percentage point absolute difference that translates to 7–9 additional pounds lost for a 200-pound patient.
- The difference wasn't just magnitude. It was trajectory. Semaglutide arms showed weight loss velocity decline after week 32, consistent with metabolic adaptation patterns observed in earlier STEP trials. Survodutide arms maintained linear weight reduction through week 48 without plateau. The glucagon receptor component appears to prevent the 200–400 calorie/day NEAT reduction that typically occurs during prolonged caloric deficit.
- Gastrointestinal adverse events occurred at similar rates in both arms (nausea 38% survodutide vs 35% semaglutide, vomiting 18% vs 16%), suggesting the dual-receptor mechanism doesn't amplify GI side effects despite higher weight loss magnitude. Discontinuation rates were 6.2% for survodutide versus 5.8% for semaglutide. Statistically indistinguishable.
- One critical caveat: survodutide requires dose titration over 16 weeks versus 12 weeks for semaglutide due to glucagon receptor-mediated effects on hepatic glucose output. Patients with pre-existing liver disease or impaired hepatic function may not tolerate the glucagon component. Making semaglutide the more appropriate choice in that population.